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treatment with Peg/RBV compared with no treatment in
PNALT/CHC. METHODS: Sustained viral response (SVR) was
40% for 48-week treatment in genotype 1 and 72% for 24-week
treatment in genotype 2/3. Disease progression was modeled
based on METAVIR scores F0 to F4, followed by cirrhosis 
complications and death. Mean ﬁbrosis progression rates were
derived from literature reports of biopsy series in patients with
PNALT. The reference is a cohort of patients with mean age 45
years with PNALT and CHC, with distribution of ﬁbrosis at
baseline equal to that found in the trial. Quality of life and costs
for each health state were based on literature estimates and on
European treatment patterns. Costs in 2003 Euros and beneﬁts
were discounted at 3%. Sensitivity analyses on key clinical and
economic parameters were performed. The analysis was reported
from the perspective of a European National Health Service
(Italian setting). RESULTS: In genotype 1, Peg/RBV compared
with no treatment prolonged the time to cirrhosis by 4.8 years,
increased life years (LY) by 1.4 and quality-adjusted life years
(QALY) by 1 year. The incremental cost per QALY was 12,102€.
In genotypes 2/3, Peg/RBV prolonged the time to cirrhosis by 
8.6 years, increased LY by 2.5 and QALY by 1.8 years. The 
incremental cost per QALY was 1084€. Based on the distribu-
tion in the trial of 71% genotype 1, and 28% genotype 2/3, 
the overall CE ratio per QALY was 7419€. CONCLUSIONS:
Treatment of adults with PNALT/CHC using Peg/RBV is pro-
jected to delay time until cirrhosis, increase life expectancy, and
is cost-effective.
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OBJECTIVES: The objective of this study was to evaluate the
differences in reported levels of absenteeism and direct medical
costs between employees diagnosed with gastroesophageal 
reﬂux disease (GERD) and/or peptic ulcer disease (PUD) and a
matched-cohort with neither disease. METHODS: Data were
extracted from the MarketScan Research Database, a Health
Insurance Portability and Accountability Act compliant database
consisting of medical and prescription claims of employees
linked to the absenteeism ﬁles of their employers. Employees
with an ICD-9 code for GERD/PUD, and a matched cohort with
neither disease, were identiﬁed from January 1, 1997 to Decem-
ber 31, 2000. Demographic, absenteeism, and resource-
utilization variables were collected for all eligible subjects.
Analysis of variance was used to test the null hypothesis that the
four populations have equal means of absenteeism rates.
RESULTS: In all, 6205 employees with GERD, 2702 with PUD,
3297 with both GERD and PUD, and 42,902 matched control
subjects were identiﬁed. There was no signiﬁcant difference
between the GERD and PUD groups in health care costs, except
total prescription costs that were higher in the GERD group (p
< 0.001). Work-absenteeism rates appeared to increase in the
expected fashion, with lowest rates in the control group and
highest rates in the combined group. The magnitude of this dif-
ference was 0.3 sickness-related absence days per individual per
year between the groups with and without gastrointestinal
disease. For all-cause absences, the difference was higher with
1.5 absence days per year. Projections of this data to an average
sized Fortune 500 company of 250,000 employees would trans-
late to total direct costs of $312 million and indirect costs of
$4.75 million per year. CONCLUSIONS: Direct medical cost
and worker absenteeism, in GERD and PUD employees creates
a signiﬁcant burden on the employee community.
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OBJECTIVES: Fecal lactoferrin (FL) is a non-invasive marker,
able to distinguish between inﬂammatory and non-inﬂammatory
causes of symptoms in patients with ileal pouch-anal anastomo-
sis (IPAA). We assessed the cost-effectiveness (CE) of the FL assay
as the initial screening test for the evaluation of symptomatic
patients with IPAA. METHODS: The frequencies of pouchitis,
irritable pouch syndrome, cufﬁtis, and Crohn’s in symptomatic
patients were estimated to be 50%, 36%, 7%, and 7% respec-
tively. The FL assay has a sensitivity of 100% and a speciﬁcity
of 85% (7mg/ml threshold) to distinguish between inﬂammatory
and non-inﬂammatory causes of symptoms. Four competing
diagnostic strategies [empiric metronidazole therapy (txMTZ),
initial pouch endoscopy/biopsy (testBiop), initial FL assay then
MTZ when warranted (testFL + MTZ), and FL assay then 
pouch endoscopy/biopsy when warranted (testFL + Biop)] were
modeled in a decision tree. Response rates to all therapies were
based on current literature and expert opinion. Effectiveness
equaled the number of days out of 30 that a patient received
responsive therapy. Procedural and drug costs were estimated
from the 2003 Medicare fee schedule and current average whole-
sale price, respectively. RESULTS: In the base case, the average
cost per patient was $244 for testFL + MTZ, $251 for txMTZ,
$408 for testFL + Biop, and $431 for testBiop. All competing
strategies were more effective than test FL + MTZ, with incre-
mental effectiveness ranging from 2.0 to 0.1 days at an incre-
mental cost ranging from $8 to $1263. The incremental CE ratio
for txMTZ and testFL + MTZ of only $8 does not reﬂect unnec-
essary antibiotic exposure resulting in delayed diagnosis, adverse
effects, antimicrobial resistance, or patient preference for the
50% relative decrease in invasive endoscopic procedures. Results
were robust in multivariate sensitivity analyses. CONCLU-
SIONS: FL measurement prior to treatment with MTZ is a less
costly strategy with only a marginal decrease in effectiveness
when compared to empiric antibiotic therapy and other diag-
nostic strategies.
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OBJECTIVES: The overall aim of this investigation was to deter-
mine the best use of post-transplant immunosuppression thera-
pies, in terms of clinical and economic outcomes, for the liver
transplant population at the University of Colorado Hospital
(UCH), regardless of expected reimbursement. METHODS:
Patients were sequentially assigned to either tacrolimus (FK) or
emulsiﬁed cyclosporine (CYA) with or without mycophenolate
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mofetil (MMF) yielding four treatment arms: MMF + CYA (60),
MMF + FK (51), CSA (39), and FK (41). All patients were fol-
lowed for one year post-transplant. Using intent to treat or
crossover analysis outcomes were similar between FK- and CYA-
treated groups, allowing comparison of MMF patients (111) to
no-MMF patients (80). Costs (included: hospital, clinic, emer-
gency department, outpatient immunosuppression; excluded:
physician fees) were obtained using relative value units (RVUs,
microcosting), and wholesale acquisition prices. Ratios of cost-
to-charges (RCCs) for cost-estimate method comparisons were
obtained from a Medicare cost report. RESULTS: All treatment
arms had similar severity and chronology of rejection episodes.
In addition, there were no signiﬁcant differences between treat-
ment arms when actual costs (RVUs), or other cost-estimation
methods were used. Cost-center speciﬁc ratio of costs to charges
(RCCs) performed better than global hospital RCCs, but both
were signiﬁcantly different from, and underestimated, RVU
costs. Pharmacy appeared to be the reason why cost-center spe-
ciﬁc RCCs did not perform well. There were no signiﬁcant dif-
ferences between cost-center speciﬁc RCCs and RVU costs when
pharmacy RCCs were adjusted. CONCLUSIONS: There is not
a preferred immunosuppressive treatment substitute (MMF +
FK, MMF + CYA, FK, CYA) for the post-liver transplant popu-
lation at UCH. Traditional cost-estimate methods do not accu-
rately approximate costs. A pharmacy RCC adjustment may be
required for disease states that use signiﬁcant inpatient pharmacy
resources. Cost-center speciﬁc RCC method cost-estimates may
be improved with this methodology.
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OBJECTIVES: To assess responsiveness to change and construct
validity of the English Work Productivity and Activity Impair-
ment questionnaire for Gastro-Esophageal Reﬂux Disease
(WPAI-GERD). METHODS: The WPAI-GERD was used in a
clinical study in Canadian GERD patients with moderate or
severe symptoms treated with esomeprazole 40mg once daily for
4 weeks. Productivity variables obtained included GERD-speciﬁc
absence from work, reduced productivity while at work, and
reduced productivity while carrying out regular daily activities
other than work during the preceding week. RESULTS: The
analysis included 217 patients, of whom 71% (n = 153) were
employed. Before start of treatment, employed patients reported
an average of 0.9 hours absence from work and 14.0% reduced
work productivity (= 5.8 hours equivalent; % reduced produc-
tivity x hours actually worked), as well as 21.0% reduced pro-
ductivity in daily activities (all patients). After treatment, the
corresponding ﬁgures decreased to 0.3 hours, 3.0% (= 1.1 hours
equivalent) and 4.9%, respectively. Thus, the improvement (dif-
ference from start of treatment) in productivity was 0.6 hours (p
= 0.01) for absence from work, 11.0% units (p < 0.001) for
reduced work productivity (= 4.7 hours equivalent, p < 0.001)
and 16.1% units (p < 0.001) for reduced productivity in activi-
ties. This improvement translates into an avoided loss of work
productivity of 5.3 hours in total on a weekly basis per patient
employed. Cross-sectional correlation coefﬁcients between WPAI
variables and symptoms (range: 0.04–0.63), as well as health-
related quality of life (range: 0.02–0.65) supported cross-
sectional construct validity of the English WPAI-GERD. 
Corresponding change score correlations between WPAI vari-
ables and relevant symptoms were low (range: 0.10–0.23), which
would indicate poor longitudinal construct validity. CONCLU-
SIONS: Cross-sectional construct validity of the English WPAI-
GERD version was conﬁrmed and results indicated that the
WPAI-GERD is responsive to change. Although these results 
also indicated poor longitudinal construct validity, the overall
ﬁndings suggest that further study of the instrument remains
warranted.
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OBJECTIVES: To evaluate lost productivity in Inﬂammatory
Bowel Disease (IBD) patients from a large gastroenterology 
outpatient practice in an urban university hospital system.
METHODS: A self-administered survey was mailed to 614 IBD
patients. The survey included the WAII questionnaire (Work and
Activity Impairment from IBD), a modiﬁed version of the WPAI
(Work Productivity and Activity Impairment Questionnaire),
which measures lost productivity in the form of missed work
(absenteeism), impairment during work (presenteeism), and daily
activity impairment during the past year. Additional questions
pertaining to IBD disease severity, demographics, medical treat-
ment, and comorbid conditions were included. Multiple regres-
sion models were used to assess the impact of IBD severity, age,
gender, comorbidities, and disease type (Crohn’s Disease or
Ulcerative Colitis) on absenteeism, presenteeism, and activity
impairment. RESULTS: Of the 314 respondents (51.1%
response rate), 46.8% were female and 53.2% male (mean age
46.1 years). Respondents reported an average of 14.1% of sched-
uled work hours were lost due to absenteeism or disability.
Among respondents who missed at least some work in the past
year (n = 98; 31.2%), the mean number of hours missed was
56.4. On average respondents reported a 25.4% decrease in
workplace productivity (presenteeism), and reported a 30.4%
reduction in daily activity level due to IBD. Multiple regression
analysis revealed that IBD severity, age and anemia were the most
signiﬁcant predictors of absenteeism (p < 0.05). For presen-
teeism, IBD severity, anemia and hypercholesterolemia were 
signiﬁcant predictors (p < 0.05). Lastly, for daily activity 
impairment, IBD severity, female gender, and the comorbidities
of anemia, arthritis, hypercholesterolemia, depression and
anxiety were signiﬁcant predictors (p < 0.05). In all three models,
severity of IBD symptoms was the most important predictor of
lost productivity. CONCLUSIONS: The severity of IBD is a 
signiﬁcant determinant of productivity loss in the form of 
absenteeism from work, presenteeism at work, and daily 
activity impairment.
